TPG-Axon Capital

Tarana Wireless, Inc. is focused on the research, development, and commercialization of non-line-of-sight (NLoS) wireless transport solutions. Its flagship product, AbsoluteAir 2 (AA2), offers advanced capabilities such as deterministic True NLOS performance, extensive coverage, and high spectral efficiency. The company provides a comprehensive solution, including installation services by construction-grade crews and a carrier-class element management system for configuring and monitoring AA2 nodes. Tarana's technology supports a variety of applications, including small-cell backhaul, wireless fiber extension, and residential broadband access, catering primarily to tier-1 operators globally. Founded in 2009, the company is headquartered in Milpitas, California, with additional offices in Berkeley and Pune, India.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of cancer and autoimmune diseases. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create functional and predictive computational models of biological systems, particularly cell signaling networks. In addition to its internal development efforts, the company collaborates with third parties to further process and commercialize its products, enhancing its ability to bring novel therapeutics and diagnostics to market.

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of cancer and autoimmune diseases. Merrimack employs a systems biology approach, utilizing multidisciplinary capabilities to create functional and predictive computational models of biological systems, particularly cell signaling networks. In addition to its internal development efforts, the company collaborates with third parties to further process and commercialize its products, enhancing its ability to bring novel therapeutics and diagnostics to market.